Download PDF
Der Klinikarzt 2020; 49(12): 550-558
DOI: 10.1055/a-1318-9382
Schwerpunkt

Medikamentöse Therapie der chronisch entzündlichen Darmerkrankungen (CED)

Stand 2020
Julia Morgenstern
1   Abteilung für Gastroenterologie, Pulmologie und allgemeine Innere Medizin, Evangelisches Krankenhaus Kalk gGmbH, Köln
,
Konrad Streetz
1   Abteilung für Gastroenterologie, Pulmologie und allgemeine Innere Medizin, Evangelisches Krankenhaus Kalk gGmbH, Köln
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die Therapie der chronisch entzündlichen Darmerkrankungen (CED) unterliegt insbesondere in den letzten 2 Jahrzehnten einem deutlichen Wandel. Steroide nehmen in der Behandlung der akuten Entzündung sowohl beim Morbus Crohn als auch der Colitis ulcerosa zwar immer noch einen wichtigen Platz ein, stellen jedoch keine langfristige Therapieoption dar.

Eine Vielzahl neuer galenischer Formulierungen bekannter Medikamente, der Einsatz von Biologika und neuer kleinmolekularer Inhibitoren (mit weiteren Wirkstoffen in der Entwicklung) erweitern die therapeutischen Möglichkeiten erfreulicherweise und führen damit zu einer Verbesserung der Lebensqualität der Patienten.

Die große Herausforderung für den Behandler ist neben der Wahl des geeigneten Medikaments zum richtigen Zeitpunkt, zunehmend auch ein zielgerichtetes Management der Therapie. Hierzu gehören Dosisanpassungen der Therapeutika, geeignete Ko-Medikationen und ein genaues Monitoring des Krankheitsverlaufs.



Publication History

Article published online:
15 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Campieri M, Ferguson A, Doe W. et al The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut 1997; 41: 209-214
    CrossrefPubMedGoogle Scholar
  • 2 Gomollón F, Dignass A, Annese V. et al ECCO. 3 rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11: 3-25
    CrossrefPubMedGoogle Scholar
  • 3 Preiß J, Bokemeyer B, Buhr H. et al Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014 Z Gastroenterol. 2014; 52: 1431-1484
    PubMedGoogle Scholar
  • 4 Torres J, Bonovas S, Doherty G. et al ECCO Guidelines on Therapeutics in Crohn’s Disease: medical Treatment. J Crohns Colitis 2020; 14: 4-22
    CrossrefPubMedGoogle Scholar
  • 5 Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in ≤what form, and how much?. J Crohns Colitis 2015; 9: 198-209
    CrossrefPubMedGoogle Scholar
  • 6 Townsend C, Parker C, MacDonald J. et al Antibiotics for induction and maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2019; 2: CD012730
    PubMedGoogle Scholar
  • 7 Munkholm P, Langholz E, Davidsen M. et al Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35: 360-362
    CrossrefPubMedGoogle Scholar
  • 8 Yarur A, Strobel S, Deshpande A. et al Predictors of Aggressive Inflammatory Bowel Disease. Gastroenterol Hepatol 2011; 7: 652-659
    PubMedGoogle Scholar
  • 9 Colombel J, Sandborn W, Reinisch W. et al SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
    CrossrefPubMedGoogle Scholar
  • 10 Colombel J, Sandborn W, Rutgeerts P. et al Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
    CrossrefPubMedGoogle Scholar
  • 11 Sandborn W, Feagan B, Rutgeerts P. et al Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
    CrossrefPubMedGoogle Scholar
  • 12 Dulai PS, Singh S, Jiang X. et al The real-world effectiveness and safety of vedolizumab for moderate-severe crohn’s disease: results from the US victory consortium. Am J Gastroenterol 2016; 111: 1147-1155
    CrossrefPubMedGoogle Scholar
  • 13 Panés J, López-Sanromán A, Bermejo F. et al Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013; 145: 766-774
    CrossrefPubMedGoogle Scholar
  • 14 Feagan B, Rochon J, Fedorak R. et al Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators, N Engl J Med 1995; 332: 292-297
    PubMedGoogle Scholar
  • 15 Hanauer SB, Feagan BG, Lichtenstein G. et al Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
    CrossrefPubMedGoogle Scholar
  • 16 Feagan BG, Sandborn WJ, Gasink C. et al Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2016; 375: 1946-1960
    CrossrefPubMedGoogle Scholar
  • 17 Rubin D, Cohen R, Sandborn W. et al Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis 2017; 11: 785-791
    CrossrefPubMedGoogle Scholar
  • 18 D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther 2016; 44: 1018-1029
    CrossrefPubMedGoogle Scholar
  • 19 Sandborn W, Su C, Sands B. et al OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 376: 1723-1736
    CrossrefPubMedGoogle Scholar
  • 20 Sands B, Sandborn W, Panaccione R. et al Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019; 381: 1201-1214
    CrossrefPubMedGoogle Scholar
  • 21 Laharie D, Bourreille A, Branche J. et al Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
    CrossrefPubMedGoogle Scholar
  • 22 Berinstein J, Steiner C, Regal R. et al Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2019; 17: 988-990.e1
    CrossrefPubMedGoogle Scholar
  • 23 Wang Y, Parker C, Feagan B, McDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 5: CD000544
    PubMedGoogle Scholar
  • 24 Kruis W, Fric P, Pokrotnieks J. et al Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
    CrossrefPubMedGoogle Scholar
  • 25 Burri E, Maillard M, Schoepfer A. et al Treatment Algorithm for Mild and Moderate-to-severe Ulcerative Colitis. Digestion 2020; 101: 2-25
    CrossrefPubMedGoogle Scholar
  • 26 Sewitch M, Abrahamowicz M, Barkun A. et al Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-1544
    CrossrefPubMedGoogle Scholar
  • 27 Herfarth H, Barnes EL, Valentine JF. et al Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology 2018; 155: 1098-1108
    CrossrefPubMedGoogle Scholar
  • 28 Ardizzone S, Maconi G, Russo A. et al Randomised controlled trial of azathioprine and 5- ≤aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
    CrossrefPubMedGoogle Scholar
  • 29 Panaccione R, Ghosh S, Middleton S. et al Combination therapy with infliximab and ≤azathioprine is superior to monotherapy with either agent in ulcerative colitis. ≤Gastroenterology 2014; 146: 392-400
    CrossrefPubMedGoogle Scholar
  • 30 Kucharzik T, Dignass A, Atreya R. et al Aktualisierte S3-Leitlinie Colitis ulcerosa August 2020 – Konsultationsfassung, AWMF-Registriernummer: 021–009.
    PubMedGoogle Scholar
  • 31 Sands BE, Peyrin-Biroulet L, Loftus Jr. EV. et al Vedolizumab versus Adalimumab for ≤Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019; 381: 1215-1226
    CrossrefPubMedGoogle Scholar
  • 32 Macaluso F, Ventimiglia M, Fries W. et al A propensity score weighted comparison of vedolizumab and adalimumab in Crohn’s disease. J Gastroenterol Hepatol 2020 May 19
    PubMedGoogle Scholar
  • 33 Bonovas S, Lytras T, Nikolopoulos G. et al Systematic review with network meta-analysis: ≤comparative assessment of tofacitinib and biological therapies for moderate-to-severe ≤ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454-465
    CrossrefPubMedGoogle Scholar
  • 34 Colombel J, D’haens G, Lee W. et al Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2020; 14: 254-266
    CrossrefPubMedGoogle Scholar
  • 35 Sulz M, Burri E, Michetti P. et al Treatment algorithms for Crohn´s disease. Digestion 2020; 101: 43-57
    CrossrefPubMedGoogle Scholar